News
Byannli authorised in Britain for schizophrenia treatment
Market authorisation for twice yearly schizophrenia treatment which offers patients much-needed medication continuity
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Market authorisation for twice yearly schizophrenia treatment which offers patients much-needed medication continuity